This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07104500 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 3 |
| Sponsor | Viking Therapeutics, Inc. |
| Enrollment | 4,500 participants |
| Design | Interventional, Randomized, Parallel, Masking: Triple |
| Conditions | Weight Loss |
| Interventions | VK2735 |
| Start | Jun 23, 2025 |
| Primary completion | Jul 1, 2027 |
| Study completion | Aug 1, 2027 |
| Results posted | Not yet |
| Registry last updated | Nov 24, 2025 |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment | 78 Weeks |
1 secondary outcome also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.
More trials of VK2735
- Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) (Phase 3 NCT07868835)
- Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) (Phase 3 NCT07868939)
- VANQUISH 2: VK2735, Phase 3 (NCT07104383)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.